图源：豆包马上到年关，三则看似分散的消息，几乎同一时间砸向行业。不仅如此，在众多品种中，百亿级大品种、首仿争夺战、改良新药这些明星赛道也未能幸免。这些骤然增多的上市申请折戟背后，是NMPA骤然增多的药品通知件。事实上，当11月17日，NMPA罕见下发77个药品通知件送达时，行业已窥得熟悉信息，诸多业内人士认为这是仿制药审评、审批收紧的信号；而当12月3日，CDE官网正式发布《化学仿制药药学研究重大...
Source Link图源：豆包马上到年关，三则看似分散的消息，几乎同一时间砸向行业。不仅如此，在众多品种中，百亿级大品种、首仿争夺战、改良新药这些明星赛道也未能幸免。这些骤然增多的上市申请折戟背后，是NMPA骤然增多的药品通知件。事实上，当11月17日，NMPA罕见下发77个药品通知件送达时，行业已窥得熟悉信息，诸多业内人士认为这是仿制药审评、审批收紧的信号；而当12月3日，CDE官网正式发布《化学仿制药药学研究重大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.